The Economist’s 8th Annual World Cancer Series: Europe convenes a wide range of stakeholders critical to effective cancer care, to drive innovation, equity and excellence
European regulators have rejected Puma’s breast cancer drug Nerlynx (neratinib) – diverging from the FDA, which opted to grant the drug a licence last year.
We present the latest insight and analysis of the rapidly evolving field of cancer therapeutics and immuno-therapy, with a particular focus on what current innovati
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl